These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26265483)

  • 21. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
    Brookhart MA; Schneeweiss S; Avorn J; Bradbury BD; Liu J; Winkelmayer WC
    JAMA; 2010 Mar; 303(9):857-64. PubMed ID: 20197532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients.
    Evans M; Carrero JJ; Bellocco R; Barany P; Qureshi AR; Seeberger A; Jacobson SH; Hylander-Rössner B; Rotnitzky A; Sjölander A
    Nephrol Dial Transplant; 2017 Nov; 32(11):1892-1901. PubMed ID: 27672090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
    Tsuruya K; Uemura Y; Hirakata H; Kitazono T; Tsubakihara Y; Suzuki M; Ohashi Y
    Nephrology (Carlton); 2017 Oct; 22(10):769-775. PubMed ID: 27312361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
    Luo J; Jensen DE; Maroni BJ; Brunelli SM
    Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients.
    Ogawa C; Tsuchiya K; Kanda F; Maeda T
    Am J Nephrol; 2014; 40(6):561-70. PubMed ID: 25592750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
    Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
    BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease.
    Hayashi T; Nagamatsu T; Matsushita A; Mizuno T; Nishibe S; Noguchi A; Kato R; Toda T; Tanaka J; Takahashi H; Hayashi H; Yuzawa Y; Yamada S
    Biol Pharm Bull; 2015; 38(5):740-5. PubMed ID: 25740003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
    Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
    Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
    Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
    Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
    Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
    G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.
    Lestz RM; Fivush BA; Atkinson MA
    Pediatr Nephrol; 2014 Oct; 29(10):2021-8. PubMed ID: 24794833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.